Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.40
(
-1.25%
)
Bitcoin
74,634.86
(
0.94%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 67576

Tuesday, 01/26/2010 3:25:11 AM

Tuesday, January 26, 2010 3:25:11 AM

Post# of 257253
NVS announces senior management transition: Dan Vasella, who has been CEO since the company’s formation in 1996 (the longest reign of any current Big Pharma CEO) is handing the reins to Joe Jimenez, who had been chief of NVS’ pharma division. Vasella will remain Chairman of the Board. The new head of NVS’ pharma division will be David Epstein, who had been head of oncology.

This announcement was made in conjunction with NVS’ 4Q09 financial results.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now